周琪,朱宛宛

• 1:中国科学院动物研究所

摘要(Abstract)：

干细胞的临床研究和应用给人类多种重大疾病的治疗带来了希望,干细胞和再生医学已成为当今最受瞩目的生命科学研究领域,但同时干细胞技术的蓬勃发展也受到了伦理、道德和法律方面的冲击。本文重点分析了干细胞和再生医学领域的研究现状与发展趋势,尤其是干细胞技术与产品带来的伦理争议,深入探讨我国应如何制定相关的政策、法规和管理办法,并关注其它需要重视或亟待解决的问题,希望有助于推动我国干细胞临床研究和治疗的健康发展。

关键词(KeyWords)： 干细胞;再生医学;干细胞治疗;伦理问题;干细胞伦理

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 周琪,朱宛宛

DOI: 10.19524/j.cnki.10-1009/g3.2013.01.003

参考文献(References)：

• [1]Volarevic V,Erceg S,Bhattacharya S.S,et al.Stem cell based therapy for spinal cord injury.Cell Transplant,2012,3:42-53.
• [2]Doi D,Morizane A,Kikuchi T,et al.Prolonged maturation culture favors a reduc-tion in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease.Stem Cells,2012,5(30):935-945.
• [3]Amirpour N,Karamali F,Rabiee F,et al.Differentiation of human embryonic stem cell-derived retinal progenitors into retinal cells by Sonic hedgehog and/or retinal pig-mented epithelium and transplantation into the subretinal space of sodium iodate-in-jected rabbits.Stem Cells Dev,2012,21(1):42-53.
• [4]Schwartz S.D,Hubschman J.P,Heilwell G,et al.Embryonic stem cell trials for macular degeneration:apreliminary report.Lancet,2012,379(9817):713-720.
• [5]Takahashi K and Yamanaka S.Induction of pluripotent stem cells from mouse em-bryonic and adult fibroblast cultures by defined factors.Cell,2006,126(4):663-676.
• [6]Tong M,Lv Z,Liu L,et al.Mice generated from tetraploid complementation com-petent iPS cells show similar developmental features as those from ES cells but are prone to tumorigenesis.Cell Res,2011,21(11):1634-1637.
• [7]Wang S,Qu X,Zhao RC.Clinical applications of mesenchymal stem cells.J Hema-tol Oncol.2012,30;5:19.
• [8]Ren G,Chen X,Dong F,et al.Concise review:mesenchymal stem cells and transla-tional medicine:emerging issues.Stem Cells Transl Med.2012,1(1):51-58.
• [9]Fiorina P,Voltarelli J,Zavazava N.Immunological applications of stem cells in type1diabetes.Endocr Rev.2011,32(6):725-754.
• [10]Mabed M,Shahin M.Mesenchymal stem cell-based therapy for the treatment of type1diabetes mellitus.Curr Stem Cell Res Ther.2012,7(3):179-190.
• [11]Mason C,Manzotti E.Regen:the industry responsible for cell-based therapies.Regen Med.2009,4(6):783-785.
• [12]Ahrlund-Richter L,De Luca M,Marshak DR,et al.Isolation and production of cells suit-able for human therapy:challenges ahead.Cell Stem Cell.2009,4(1):20-26.
• [13]丘祥兴,沈铭贤,胡庆灃.干细胞研究伦理.生命科学,2012,24(11):1308-1317.
• [14]胡庆灃,丘祥兴,沈铭贤.干细胞研究与应用的伦理思考.中国医学伦理学,2010,23(3):5-9.
• [15]International Stem Cell Banking Initiative.Consensus guidance for banking and sup-ply of human embryonic stem cell lines for research purposes.Stem Cell Rev.2009,5(4):301-314.
• [16]王太平,徐国彤,周琪等.国际干细胞研究学会《干细胞临床转化指南》.生命科学,2009,21(5):747-756.